Introductie
Materiaal
Patiënten
Data
MRI-protocol
Radiologische intekening
Ontwikkeling van het 3D-model
Correlatie van de tumorlocatie
Scoren van de planning van zenuwsparing
Berekening van de power
Statistische analyse
Resultaten
Klinisch-pathologische karakteristieken | |
---|---|
leeftijd (jaar); mediaan (IQR) | 66 (59–72) |
initieel serum-PSA (ng/ml); mediaan (IQR) | 7,8 (5,0–12) |
klinisch tumorstadium; n (%) | |
– cT1c | 8 (40%) |
– cT2a | 4 (20%) |
– cT2b | 3 (15%) |
– cT2c | 3 (15%) |
– cT3a | 2 (10%) |
biopt ISUP-graad; n (%) | |
– ISUP 1 | 2 (10%) |
– ISUP 2 | 10 (50%) |
– ISUP 3 | 5 (25%) |
– ISUP 4 | 2 (10%) |
– ISUP 5 | 1 (5%) |
MRI-tumorstadium; n (%) | |
– mT2a | 7 (35%) |
– mT2b | 3 (15%) |
– mT2c | 7 (35%) |
– mT3a | 3 (15%) |
pathologisch tumorstadium; n (%) | |
– pT2 | 13 (65%) |
– pT3a | 7 (35%) |
pathologische ISUP-graad; n (%) | |
– ISUP 1 | 0 (-) |
– ISUP 2 | 15 (75%) |
– ISUP 3 | 3 (15%) |
– ISUP 4 | 0 (-) |
– ISUP 5 | 2 (10%) |
positieve snijvlakken; n (%) | 6 (30%) |
Workflow
Pathologische correlatie
Planning van zenuwsparing
verschil in FP-score | virtueel vs. MRI, n (%) | 3D print vs. MRI, n (%) |
---|---|---|
−6 | 9 (3,2%) | 12 (4,3%) |
−5 | 8 (2,9%) | 7 (2,5%) |
−4 | 3 (1,1%) | 2 (0,7%) |
−3 | 17 (6,1%) | 16 (5,7%) |
−2 | 9 (6,1%) | 5 (1,8%) |
−1 | 14 (5,0%) | 13 (4,6%) |
0 | 159 (57%) | 159 (57%) |
1 | 16 (5,7%) | 17 (6,1%) |
2 | 12 (4,3%) | 8 (2,9%) |
3 | 11 (3,9%) | 11 (3,9%) |
4 | 4 (1,4%) | 4 (1,4%) |
5 | 8 (2,9%) | 8 (2,9%) |
6 | 10 (3,6%) | 13 (4,6%) |
Totaal | 280 (100%) | 280 (100%) |
|∆FP-score| ≥ 3 | 70 (25,%) | 73 (26%) |
p-waarde | < 0,001 | < 0,001 |